SYBX
SYBX clinical trials: SYNLOGIC, INC.
Every trial on ClinicalTrials.gov where SYNLOGIC, INC. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 10
- Trials linked
- 10
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
SYBX on the catalyst calendar · SYBX registry changes
- Primary completion Mar 15, 2024ActualPhase 3NCT05764239Efficacy and Safety of SYNB1934 in Patients With PKU (SYNPHENY-3)Synlogic · PhenylketonuriaTerminatedSYBXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 17, 2023ActualPhase 1NCT04629170Safety and Tolerability of SYNB8802 in Healthy Adult Volunteers and Adult Subjects With Enteric HyperoxaluriaSynlogic · HealthyCompletedSYBXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 9, 2021ActualPhase 1NCT04167137Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult ParticipantsSynlogic · Metastatic Solid NeoplasmTerminatedSYBXLeadIQVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 27, 2022ActualPhase 1NCT05462132Safety, Tolerability and Pharmacodynamics of SYNB1353 in Healthy Adult VolunteersSynlogic · HomocystinuriaCompletedSYBXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 7, 2022ActualEarly Phase 1NCT05377112Safety, Tolerability, and Pharmacodynamics of SYNB8802v1 in Subjects With History of Gastric Bypass Surgery or Short-bowel SyndromeSynlogic · Enteric HyperoxaluriaCompletedSYBXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 7, 2022ActualPhase 2NCT04534842Efficacy and Safety of SYNB1618 and SYNB1934 in Adult Patients With PhenylketonuriaSynlogic · PhenylketonuriaCompletedSYBXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 10, 2021ActualPhase 1NCT04984525Safety and Tolerability of SYNB1934 in Healthy Adult VolunteersSynlogic · HealthyCompletedSYBXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 21, 2019ActualPhase 1/Phase 2NCT03516487Safety and Tolerability of SYNB1618 in Healthy Adult Volunteers and Adult Subjects With PhenylketonuriaSynlogic · PhenylketonuriaCompletedSYBXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 19, 2019ActualPhase 1/Phase 2NCT03447730Safety, Tolerability and Pharmacodynamics of SYNB1020Synlogic · CirrhosisTerminatedSYBXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2, 2017ActualPhase 1NCT03179878Safety and Tolerability of SYNB1020-CP-001Synlogic · Healthy VolunteerCompletedSYBXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 10 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner